文献速递真菌感染

伏立康唑药代动力学与肝毒性的遗传及临床预测因素:聚焦CYP2C19正常和中间代谢者

Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该观察性研究纳入114例接受伏立康唑治疗的成年中国患者,评估10个遗传变异与CYP2C19正常和中间代谢者伏立康唑谷浓度的关联,并探索药代动力学变异和肝毒性的预测因素。结果表明伏立康唑谷浓度个体间差异超过40倍,整合治疗药物监测与遗传及临床因素可能优化给药并降低肝毒性风险。

要点

  • 伏立康唑谷浓度在CYP2C19正常和中间代谢者中仍存在超过40倍的个体间变异。
  • SLCO1B3、NR1I2、白蛋白、C反应蛋白和日剂量是药代动力学变异的预测因素。
  • 肝毒性发生率为27.2%,与较高谷浓度相关,NR1I2 GG基因型和高基线血小板计数与风险降低相关。

核心结论

  • CYP2C19正常和中间代谢者中伏立康唑暴露的个体间变异仍显著,整合治疗药物监测与遗传及临床因素可能优化给药并降低肝毒性风险。

研究设计与样本

  • 观察性研究纳入114例于2022年7月至2023年5月接受伏立康唑治疗的成年中国患者。
  • 在CYP2C19正常代谢者和中间代谢者中评估10个遗传变异与伏立康唑谷浓度的关联。
  • 采用广义线性模型识别药代动力学变异的预测因素,二元逻辑回归评估肝毒性风险。

主要发现

  • 伏立康唑谷浓度变异超过40倍(0.2-9 μg/mL)。
  • 正常代谢者中CYP3A4(rs4646437)和NR1I2(rs7643645、rs3814055)与谷浓度呈名义关联,中间代谢者中SLCO1B3(rs4149117)、SLCO2B1(rs3781727)和NR1I2(rs3814055)呈名义关联,但Bonferroni校正后均不显著。
  • 广义线性模型识别SLCO1B3(rs4149117)、NR1I2(rs3814055)、白蛋白、C反应蛋白和日剂量为药代动力学变异的预测因素。
  • 肝毒性发生率为27.2%,与较高谷浓度相关,NR1I2(rs7643645)GG基因型和较高基线血小板计数与风险降低相关。

临床怎么用

  • 对CYP2C19正常和中间代谢者使用伏立康唑时,应结合治疗药物监测、SLCO1B3和NR1I2基因型、白蛋白、C反应蛋白及日剂量综合评估药代动力学变异。
  • 监测伏立康唑谷浓度有助于识别肝毒性高风险患者,尤其需关注较高谷浓度者。

局限性

  • 研究样本量有限(114例),需更大规模多中心研究验证。
  • 遗传变异与谷浓度的关联经Bonferroni校正后均不显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Voriconazole is recommended as first-line therapy for invasive fungal infections but exhibits substantial pharmacokinetic (PK) variability and hepatotoxicity. Although CYP2C19 polymorphisms partially explain this variability, evidence regarding additional genetic determinants remains inconsistent. Studies integrating genetic and clinical factors for voriconazole PK and hepatotoxicity are limited. OBJECTIVES: To assess the association between 10 genetic variants and voriconazole trough concentrations in CYP2C19 normal (NM) and intermediate (IM) metabolizers and to identify predictors of PK variability and hepatotoxicity. METHODS: This observational study included 114 adult Chinese patients receiving voriconazole between July 2022 and May 2023. Associations between genetic variants and voriconazole trough concentrations were assessed within CYP2C19 NMs and IMs. Generalized linear models (GLMs) identified predictors of PK variability, and binary logistic regression assessed hepatotoxicity risk. RESULTS: Voriconazole trough concentrations varied over 40-fold (0.2-9 μg/mL). Nominal associations were observed for CYP3A4 (rs4646437) and NR1I2 (rs7643645, rs3814055) in NMs and for SLCO1B3 (rs4149117), SLCO2B1 (rs3781727) and NR1I2 (rs3814055) in IMs, but none remained significant after Bonferroni correction. GLM analysis identified SLCO1B3 (rs4149117), NR1I2 (rs3814055), albumin, C-reactive protein (CRP) and daily dose as predictors of PK variability. Hepatotoxicity occurred in 27.2% of patients and was associated with higher trough concentrations, whereas the NR1I2 (rs7643645) GG genotype and higher baseline platelet count were associated with reduced risk. CONCLUSIONS: Marked interindividual variability in voriconazole exposure persists among CYP2C19 NMs and IMs. Integrating therapeutic drug monitoring (TDM) with genetic and clinical factors may optimize dosing and reduce hepatotoxicity risk. Larger multicentre studies are still needed.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Li H, Lu Q, Xu B, et al. Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers. J Antimicrob Chemother. 2026. PMID: 41766350. doi:10.1093/jac/dkag065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。